The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Below are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
News Highlights:
Treatment Action Group and Stop TB Partnership Issue Update on 2011 Global TB R&D Investment Trends
Desmond Tutu TB Centre receives Stop TB Partnership Kochon Prize
First ever civil society march held at the Union World Conference on Lung Health
Civil society declaration on tuberculosis issued at Union Conference
Relevant Presentations from 43rd Union World Conference:
Childhood TB
Pharmacokinetics of second line TB therapy in children (Hesseling, Anneke)
A framework for the evaluation of new TB drugs in children (Mendel, Carl)
TB treatment considerations for neonates and infants (Bekker, Adrie)
Childhood TB: we need to do more (Hesseling, Anneke)
MDR-TB
Use of Bedaquiline (TMC-207) for treatment of MDR-TB (Haxaire-Theeuwes, Myriam)
Delamanid: a promising new treatment for MDR-TB (Wells, Charles)
The access pipeline: timelines for new drugs (Gardiner, Elizabeth)
Market interventions to increase access to MDR-TB treatment: the UNITAID approach (Matiru, Robert)
12-month standardised MDR-TB regimen: experience in Cameroon (Kuaban, Christopher)
Biomarkers and Clinical Trial Design
Introduction–Biomarkers in tuberculosis: from discovery to clinical application (Gennaro, Marila)
Biomarkers and clinical trials (Nahid, Payam)
Adaptive and other novel trial designs for late-phase clinical trials (Phillips, Patrick)
General TB
Increasing new resources through international advocacy partnerships (Barua, Aparna)